Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 37Terminated 10Unknown 7Recruiting 7Active not recruiting 7Withdrawn 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2

Conditions

Multiple Myeloma 18Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Follicular 5Recurrence 4Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma 3Waldenstrom Macroglobulinemia 2Neoplasms, Plasma Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia 2Sezary Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Neoplasm, Residual 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Leukemia, Plasma Cell 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Burkitt Lymphoma 1Blood Protein Disorders 1

Interventions

Dexamethasone 14Rituximab 6Cytarabine 5venetoclax 4Lenalidomide 4Bortezomib 4Bendamustine Hydrochloride 4selinexor 3pomalidomide 3pembrolizumab 3ibrutinib 3fludarabine 3carfilzomib 3Paclitaxel 3Gemcitabine 3Drug Therapy 3Cyclophosphamide 3Calcium Dobesilate 3ixazomib 2gilteritinib 2fludarabine phosphate 2elotuzumab 2daratumumab 2belinostat 2Tablets 2Surveys and Questionnaires 2Panobinostat 2Oxaliplatin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × Lenalidomide × Clear all
NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3 Withdrawn
Lymphoid

Lymphoma, Follicular, Recurrence

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02389543 2023-01-26

SLAM

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT02986451 2018-08-14

Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

Sun Yat-sen University

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡